Secured the potential for up to $5 million in new funding ($1.5 million of which has been funded to date) and further secured a 9% royalty on future U.S. sales of SUBA®-Itraconazole for basal cell carcinoma nevus syndrome (BCCNS) through revised agreement with majority shareholder and licensor Mayne Pharma Ventures Pty Ltd. (Mayne Pharma)
Secured exclusive option to license next-generation itraconazole analogues from University of Connecticut (UCONN) for potential pipeline expansion, and exploring additional assets to acquire or license
Significantly expanded intellectual property for oral itraconazole covering the treatment of a broad range of cancers and non-cancerous proliferation disorders
Actively seeking pre-IND meeting for SUBA-Itraconazole for Prostate Cancer during first half of 2019, with the goal of initiating human trials in 2019, and also exploring other product candidates for acquisition or license
PR Newswire
TAMPA, Fla., March 7, 2019
